Latest Research And Development News

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

BCAL Diagnostics reported a slight revenue decline and a persistent net loss in its half-year results, with auditors flagging concerns over its ability to continue without additional funding.

Energy Action Limited reported a strong 20.1% revenue increase in the first half of FY26, driven by robust energy procurement activity, yet net profit after tax fell sharply due to higher amortisation and tax expenses.

Elixir Energy has successfully drilled the Lorelle-3 pilot well to 3,580 metres in Queensland’s Taroom Trough, intersecting multiple Permian hydrocarbon reservoirs including a thick section of the primary Tinowon ‘Dunk’ Sandstone. Wireline logging and upcoming stimulation tests aim to confirm commercial gas flow potential.

AVITA Medical reported a mixed fourth quarter with revenue pressures easing and full-year growth, underpinned by a new $60 million credit facility and advancing clinical trials.

AVITA Medical reported steady Q4 losses amid reimbursement challenges but achieved 11% revenue growth for 2025 and secured a $60 million credit facility to fuel future expansion.

St George Mining has won preferential tax treatment from the Minas Gerais government, cutting development costs for its flagship Araxá Project in Brazil. This support bolsters the company’s ambitions to establish a world-class niobium and rare earths operation.